The expression of WT1 was assessed at day + 60 in 50 AML patients: in 40 patients both CD34+ cells and MNCs were evaluated, while in further 10 patients, WT1 was evaluated only in CD34+ cells (5 patients) or MNCs (5 patients). This evidence concerns the gene WT1 and acute myeloid leukemia.